share_log

Needham Reiterates Buy on Arcutis Biotherapeutics, Maintains $16 Price Target

Moomoo 24/7 ·  Apr 12 06:44

Needham analyst Serge Belanger reiterates Arcutis Biotherapeutics (NASDAQ:ARQT) with a Buy and maintains $16 price target.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment